# OnCo record paper-lu-laura-osimertinib-stage-iii-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-lu-laura-osimertinib-stage-iii-nejm-2024" ;
  schema:name "Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC"@en ;
  schema:description "For stage III lung cancer with an EGFR mutation, the standard consolidation immunotherapy works poorly. LAURA gave the EGFR tablet instead and pushed median time to progression from 5.6 months to 39.1."@en ;
  schema:url <https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2402614>, <https://pubmed.ncbi.nlm.nih.gov/38828946/>, <https://clinicaltrials.gov/study/NCT03521154> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2402614> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Lu S, Kato T, Dong X, et al." ;
  onco:related <https://onco.cc/key-papers/paper-pacific-nejm-2017/>, <https://onco.cc/key-papers/paper-adaura-nejm-2020/>, <https://onco.cc/key-papers/paper-flaura-nejm-2018/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/radiation/> ;
  onco:technologies <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/driver-mutation/> ;
  onco:trials <https://onco.cc/trials/laura/> ;
  onco:people <https://onco.cc/people/suresh-ramalingam/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .